Marjo Yliperttula

University of Helsinki

Papers

1

Total Citations

10

H-Index

1

About

Marjo Yliperttula is a leading figure in pharmaceutical biophysics and drug delivery, whose work bridges the gap between cellular biology and automated screening technologies. Her research focuses on the development and validation of advanced cell-based assays for drug discovery, with a particular emphasis on permeability and toxicity screening. In a pivotal 2009 study, she demonstrated the feasibility of automating three critical cellular assays—the Caspase-Glo® 3/7 apoptosis assay, the sulforhodamine B (SRB) cytotoxicity assay, and the mechanistic Caco-2 permeability protocol—on a TECAN Genesis robotic workstation. This work, which has garnered over 10 citations, provided a foundational framework for high-throughput, reproducible drug screening in industrial and academic settings. Yliperttula’s contributions have advanced the integration of automation into preclinical pharmacology, enabling more efficient evaluation of drug candidates. Her expertise in biopharmaceutics and cellular models continues to influence the design of robust, scalable assays that accelerate the drug development pipeline, making her a respected authority in the field of pharmaceutical technology and translational research.

Research Focus

Key Achievements

1
H-Index
1
Papers
10
Total Citations
10
Avg Citations/Paper
🏆 Most Cited Paper
Feasibility Evaluation of 3 Automated Cellular Drug Screening Assays on a Robotic Workstation
10 citations · 2009
📈 Most Prolific Year: 2009 (1 Papers)
🤝 Key Collaborators: 5
🏛 Institutions: University of Helsinki

Top Papers

  1. 1

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 15 days ago